Tumor-Associated Macrophage Iron Recycling and Its Influence on Local Antitumor Immune Activity

Abstract

Tumor-associated macrophages are major regulators of the tumor microenvironment and frequently acquire iron through erythrocyte degradation, hemoglobin uptake, ferroptotic cell clearance, and recycling of iron released from damaged tumor and stromal cells. This iron-handling activity is not merely a metabolic housekeeping function. It influences macrophage polarization, oxidative signaling, antigen presentation, lymphocyte activity, angiogenesis, and the sensitivity of malignant cells to iron-dependent cell death. In many solid tumors, iron-recycling macrophages display an immunosuppressive phenotype characterized by anti-inflammatory cytokine production, impaired T-cell stimulation, and support of tumor growth. However, macrophage iron metabolism is context dependent, and selected iron-rich macrophage states may retain inflammatory and antitumor functions. Understanding the molecular links between iron trafficking and local immunity may support biomarker development and combination treatment strategies involving immune checkpoint inhibitors, ferroptosis inducers, macrophage-directed therapies, and iron-modulating agents. This review summarizes the disease burden, biological mechanisms, clinical implications, diagnostic considerations, therapeutic approaches, emerging interventions, and practical guideline-based principles relevant to tumor-associated macrophage iron recycling.

Introduction

Macrophages constitute a substantial fraction of the immune infiltrate in many cancers and are among the most functionally adaptable cells within the tumor microenvironment. Their phenotype is shaped by hypoxia, tumor-derived metabolites, cytokines, necrotic material, extracellular vesicles, and signals from endothelial and stromal cells. Iron is an important determinant of this adaptation because macrophages are central to systemic iron recycling and can store, export, or redistribute iron within tissues. In tumors, these functions become dysregulated and may create a local iron economy that benefits malignant growth while limiting effective antitumor immunity.

Tumor-associated macrophage iron recycling involves the uptake of hemoglobin-haptoglobin complexes, heme, ferritin, free iron, and senescent or damaged erythrocytes. Intracellular heme oxygenase activity releases ferrous iron, which may be incorporated into ferritin, exported through ferroportin, or used in redox reactions. The balance among these pathways affects reactive oxygen species, lipid peroxidation, mitochondrial metabolism, and cytokine production. Because macrophages also interact closely with T cells, natural killer cells, dendritic cells, and cancer cells, changes in their iron status can influence the overall quality of local antitumor immunity.

Epidemiology / Disease Burden

High densities of tumor-associated macrophages are observed in breast, ovarian, pancreatic, colorectal, lung, liver, brain, renal, and hematologic malignancies. Although macrophage abundance alone does not consistently predict outcome, enrichment of immunosuppressive macrophage programs is commonly associated with advanced stage, angiogenesis, metastatic behavior, and resistance to systemic therapy. Iron-loaded macrophages have been reported in hemorrhagic tumors, regions of intratumoral necrosis, liver metastases, and cancers with extensive microvascular remodeling. Their clinical significance varies according to tumor type, anatomical compartment, iron source, and the accompanying inflammatory context.

The burden created by macrophage-mediated immune suppression is clinically important because it can reduce the effectiveness of immune checkpoint blockade and other immunotherapies. Macrophages may occupy areas of high tumor antigen concentration and physically limit lymphocyte access to malignant cells. They can also consume or sequester nutrients, release transforming growth factor beta and interleukin-10, and support abnormal vasculature. Iron-dependent metabolic remodeling adds another layer of complexity by affecting both macrophage function and the vulnerability of tumor cells to ferroptosis.

Pathophysiology

Macrophage iron acquisition begins with recognition and internalization of heme, hemoglobin complexes, ferritin, or cellular debris. Heme oxygenase 1 degrades heme into biliverdin, carbon monoxide, and ferrous iron. The resulting iron may be stored within ferritin, particularly ferritin heavy chain, or exported through ferroportin. Hepcidin, produced by the liver and frequently induced locally by inflammatory and tumor-derived signals, binds ferroportin and promotes its degradation, thereby increasing intracellular iron retention. This process can generate iron-rich macrophages with altered transcriptional and metabolic profiles.

Iron influences macrophage biology through redox-sensitive transcription factors, mitochondrial respiration, hypoxia-inducible pathways, and nuclear factor kappa B signaling. Iron retention may reinforce an alternatively activated, tissue-reparative phenotype in some settings, including increased expression of scavenger receptors, vascular endothelial growth factor, transforming growth factor beta, and immunoregulatory cytokines. These mediators can promote extracellular matrix remodeling, vascular growth, tumor-cell invasion, and suppression of cytotoxic lymphocyte function. Nevertheless, iron retention is not synonymous with a single macrophage phenotype. Inflammatory stimuli, microbial signals, interferon gamma, tumor genotype, and the availability of lipid substrates can redirect iron-loaded macrophages toward either inflammatory or suppressive states.

Iron recycling also affects neighboring immune cells. Excess extracellular iron can impair T-cell proliferation, alter natural killer cell cytotoxicity, and promote oxidative stress. Conversely, macrophage iron export may supply malignant cells with a growth-promoting nutrient, supporting DNA synthesis and oxidative phosphorylation. Tumor cells may increase transferrin receptor expression, ferritin uptake, or other iron acquisition programs. In parallel, iron-rich macrophages can modify the threshold for ferroptosis, a regulated form of cell death driven by iron-dependent lipid peroxidation. The final effect depends on the relationship between iron availability, antioxidant defenses, glutathione metabolism, and lipid composition.

Risk Factors

Factors associated with prominent macrophage iron dysregulation include intratumoral hemorrhage, chronic inflammation, extensive necrosis, anemia with repeated transfusion, hepatic dysfunction, systemic iron overload, and tumors with dense vascular networks. Local hepcidin production, hypoxia, rapid tumor turnover, and exposure to chemotherapy or radiotherapy can increase the release of heme and iron-containing cellular debris. Genetic or epigenetic changes affecting ferroportin, ferritin, heme oxygenase 1, transferrin receptors, or iron regulatory proteins may further modify the phenotype.

Patient-specific factors also influence interpretation. Chronic inflammatory disease can increase hepcidin and alter iron distribution without producing systemic iron excess. Malnutrition, renal disease, infection, and prior anticancer therapy may change circulating iron indices and macrophage activity. Therefore, serum ferritin or transferrin saturation should not be interpreted as direct measures of intratumoral iron or macrophage function.

Clinical Features

There is no pathognomonic clinical syndrome caused by tumor-associated macrophage iron recycling. Its effects are usually expressed through tumor progression, treatment resistance, immune exclusion, and variable patterns of necrosis or hemorrhage. Patients may present with disease-specific symptoms, anemia, inflammatory laboratory abnormalities, or radiographic features suggestive of bleeding and necrosis. These findings are nonspecific and require integration with histopathology, imaging, disease stage, and treatment history.

Clinically, the most relevant manifestations are accelerated tumor growth, metastatic dissemination, reduced response to immune checkpoint inhibitors, and persistence of disease despite adequate immune infiltration. A tumor may contain abundant immune cells yet remain functionally cold if macrophages suppress antigen presentation or prevent effective T-cell engagement. Conversely, macrophages in iron-rich but inflammatory niches may contribute to tumor cell killing and improved treatment response. This heterogeneity explains why macrophage density alone is an inadequate clinical biomarker.

Diagnosis

Assessment currently relies on research-oriented tissue profiling rather than a standardized diagnostic test. Immunohistochemistry can characterize macrophage abundance using markers such as CD68 and CD163, although these markers do not fully define function. Iron deposition may be evaluated with histochemical stains, while ferritin, heme oxygenase 1, ferroportin, transferrin receptor, and related proteins can provide information about iron handling. Multiplex immunohistochemistry, imaging mass cytometry, spatial transcriptomics, and single-cell RNA sequencing can identify iron-associated macrophage states and their proximity to T cells, cancer cells, and blood vessels.

In routine practice, evaluation should focus on validated clinical questions. Pathologists should report macrophage distribution and iron deposition when they have diagnostic or prognostic relevance, while recognizing substantial sampling limitations. Serum ferritin, hemoglobin, transferrin saturation, and inflammatory markers may assist in assessing systemic iron status but cannot establish intratumoral macrophage iron recycling. Molecular profiling and immune-related biomarkers should be interpreted alongside tumor mutational burden, mismatch repair status, programmed death ligand 1 expression, and the treatment context.

Treatment & Management

Management remains centered on effective treatment of the underlying malignancy. Immune checkpoint inhibitors can restore part of the exhausted T-cell response, but their efficacy may be constrained by macrophage-mediated immune suppression. Combination strategies under investigation include blockade of the colony-stimulating factor 1 receptor, inhibition of phosphatidylserine signaling, disruption of CD47-signal regulatory protein alpha interactions, and modulation of chemokine pathways that recruit suppressive macrophages. These approaches aim to reduce macrophage abundance, reprogram macrophage function, or improve phagocytosis rather than simply eliminate all macrophages.

Iron-directed approaches require careful selection. Inhibiting heme oxygenase 1, altering ferroportin activity, reducing hepcidin signaling, or modifying ferritin biology may limit tumor-supportive iron transfer, but systemic toxicity and effects on normal erythropoiesis are important concerns. Ferroptosis-inducing strategies seek to exploit the dependence of cancer cells on antioxidant defenses and iron metabolism. Potential combinations include glutathione peroxidase 4 inhibition, system Xc-minus blockade, radiotherapy, targeted therapy, or immune checkpoint blockade. However, excessive iron-mediated oxidative injury could damage normal tissue, promote inflammatory toxicity, or impair immune-cell viability.

At present, treatment decisions should not be based on unvalidated macrophage or iron biomarkers outside clinical trials. Clinicians should correct clinically significant anemia, avoid unnecessary iron supplementation in patients without documented deficiency, and consider transfusion and iron therapy according to established hematology and oncology indications. The objective is not to eliminate physiological iron recycling but to prevent tumor-supportive iron redistribution while preserving host hematopoiesis and immune competence.

Recent Advances / Emerging Therapies

Recent research has moved from broad macrophage classification toward spatial and metabolic characterization. Single-cell and spatial methods are identifying distinct macrophage populations associated with hemorrhagic regions, hypoxic niches, invasive tumor margins, and tertiary lymphoid structures. These studies indicate that iron handling is coordinated with lipid metabolism, mitochondrial activity, antigen presentation, and interferon signaling. Such findings may enable composite biomarkers that combine macrophage iron status with T-cell localization and tumor-cell ferroptosis susceptibility.

Nanoparticle-based delivery systems are being investigated to transport macrophage-reprogramming agents, iron chelators, ferroptosis activators, or nucleic acids preferentially into the tumor microenvironment. Additional approaches include hepcidin antagonism, ferroportin stabilization, engineered antibodies, and treatment schedules designed to synchronize macrophage reprogramming with checkpoint inhibition. The main translational challenges are variable drug distribution, macrophage plasticity, compensatory immune pathways, and the risk that indiscriminate iron manipulation will worsen anemia or systemic inflammation.

Guideline Recommendations

No major oncology guideline currently recommends routine clinical testing or treatment directed specifically at tumor-associated macrophage iron recycling. Evidence-based practice should therefore follow established disease-specific pathways for staging, molecular classification, surgery, radiotherapy, systemic therapy, immunotherapy, and management of anemia. Investigational macrophage-targeted or iron-modulating therapies should preferably be administered within ethically approved clinical trials with prospective safety monitoring.

For clinicians, practical principles include distinguishing systemic iron deficiency from inflammation-associated iron sequestration, avoiding empiric iron treatment without appropriate laboratory assessment, documenting prior transfusions and anticancer therapies, and interpreting immune biomarkers in the context of tumor architecture. Trial designs should measure macrophage phenotype, iron localization, ferroptosis-related markers, immune-cell activity, and patient-centered outcomes rather than relying solely on macrophage counts. Standardization of tissue sampling, assay thresholds, and response definitions will be essential before these biomarkers can guide routine care.

Conclusion

Tumor-associated macrophage iron recycling is a biologically important link between nutrient metabolism and local antitumor immunity. Through heme processing, ferritin storage, ferroportin-dependent export, and regulation by hepcidin, macrophages can influence tumor-cell proliferation, oxidative stress, ferroptosis susceptibility, lymphocyte activity, angiogenesis, and treatment response. The effect is context dependent and cannot be inferred from macrophage abundance or systemic iron measurements alone. Spatially resolved tissue analysis and integrated metabolic-immune biomarkers may eventually identify patients most likely to benefit from macrophage reprogramming, iron modulation, or ferroptosis-based combinations. Until clinical evidence and guideline standards mature, these strategies should remain investigational, while routine care continues to prioritize validated cancer treatments and careful management of systemic iron and hematologic status.